Want to see HK:2627 full AI Analyst Report?
Ab&B Bio-Tech CO., LTD. JS Class H (2627) AI Stock Analysis
Ab&B Bio-Tech CO., LTD. JS Class H
(HKEX:2627)
The overall score of 52 reflects significant financial weaknesses, including persistent losses and high debt, as the primary drag on the stock's outlook. Positive technical momentum provides some uplift, but overbought signals and inconclusive valuation limit optimism.
Ab&B Bio-Tech CO., LTD. JS Class H (2627) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 10.56B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -37.6
- Beta (1Y)
- 1.32
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 583
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Ab&B Bio-Tech CO., LTD. JS Class H Business Overview & Revenue Model
Company Description
Ab&B Bio-Tech Co., Ltd. engages in the research, development, manufacturing and commercialization of innovative and traditional vaccines. Its products include quadrivalent subunit influenza and lyophilized human rabies vaccines. The company was found...
Ab&B Bio-Tech CO., LTD. JS Class H Financial Statement Overview
Summary
Financial performance is weak with persistent net losses (-258.7M in 2024), high debt-to-equity ratio (5.86), and negative cash flows (-199.5M operating cash flow). Despite revenue growth (259.6M in 2024), operational inefficiencies and financial risks dominate.
Income Statement
10Very NegativeBalance Sheet
15Very NegativeCash Flow
5Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 71.12M | 259.61M | 52.17M |
| Gross Profit | 60.78M | 151.46M | -20.34M |
| EBITDA | -93.98M | -181.80M | -370.16M |
| Net Income | -121.52M | -258.72M | -424.74M |
Balance Sheet | |||
| Total Assets | 1.46B | 1.61B | 1.12B |
| Cash, Cash Equivalents and Short-Term Investments | 108.36M | 132.19M | 77.57M |
| Total Debt | 931.93M | 858.81M | 421.42M |
| Total Liabilities | 1.42B | 1.47B | 756.47M |
| Stockholders Equity | 33.64M | 146.59M | 363.27M |
Cash Flow | |||
| Free Cash Flow | -78.88M | -399.68M | -597.16M |
| Operating Cash Flow | -31.88M | -199.51M | -305.99M |
| Investing Cash Flow | -46.73M | -152.67M | -506.00K |
| Financing Cash Flow | 54.84M | 439.06M | 335.17M |
Ab&B Bio-Tech CO., LTD. JS Class H Peers Comparison
Overall Rating
HK:369274.5Outperform
HK:219657Neutral
HK:998956Neutral
HK:255252Neutral- HK:262752Neutral
HK:618551Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3692 | 75Outperform | HKD 196.24B | 24.91 | 18.26% | 1.50% | 24.97% | 43.23% |
| HK:2196 | 57Neutral | HKD 65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% |
| HK:9989 | 56Neutral | HKD 14.42B | 185.14 | 1.58% | 4.22% | 3.10% | -46.64% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:2552 | 52Neutral | HKD 2.11B | -18.06 | -10.61% | ― | 83.49% | -110.21% |
| HK:2627 | 52Neutral | HKD 11.54B | -37.62 | -101.49% | ― | ― | ― |
| HK:6185 | 51Neutral | HKD 13.23B | 632.61 | 0.60% | ― | 36.09% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2627 | Ab&B Bio-Tech CO., LTD. JS Class H | 29.32 | -10.52 | -26.41% | |
| HK:2552 | Hua Medicine | 2.17 | -1.44 | -39.75% | |
| HK:2196 | Shanghai Fosun Pharmaceutical (Group) Co Class H | 16.47 | -6.58 | -28.55% | |
| HK:9989 | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H | 3.94 | -1.40 | -26.20% | |
| HK:3692 | Hansoh Pharmaceutical Group Company Limited | 32.36 | -2.99 | -8.45% | |
| HK:6185 | CanSino Biologics, Inc. Class H | 25.78 | -21.42 | -45.38% |
Ab&B Bio-Tech CO., LTD. JS Class H Corporate Events
Ab&B Bio-Tech Partners with Walvax Unit to Take Flu Vaccine Overseas
Ab&B Bio-Tech has signed a strategic cooperation agreement with Walvax Hong Kong Limited to drive overseas registration, sales and commercialization of its core trivalent subunit influenza vaccine, Huierkangxin 3. Approved in January 2026 and cur...
Ab&B Bio-Tech Wins U.S. FDA IND Nod for mRNA Mpox Vaccine, Bolstering Global Vaccine Ambitions
Ab&B Bio-Tech CO., LTD. JS, a China-based vaccine specialist, develops innovative and traditional vaccines using advanced technologies, with a strategic focus on premium products that can substitute traditional and imported vaccines in China and...
Ab&B Bio-Tech Forecasts Strong Revenue Growth and Narrowing Loss for 2025
Ab&B Bio-Tech CO., LTD. JS has issued a profit alert indicating that its 2025 revenue is expected to surge by about 72% to 90% year on year to between RMB446 million and RMB493 million, while its net loss should narrow by roughly 24% to 39% from...
Ab&B Bio-Tech Added to Hang Seng Composite Index, Boosting Market Profile
Ab&B Bio-Tech CO., LTD. JS, a Chinese vaccine company specializing in innovative and premium vaccines such as quadrivalent and trivalent subunit influenza candidates and a lyophilized human rabies vaccine candidate, is positioning itself to subst...
Ab&B Bio-Tech Wins NMPA Approval for First All-Ages Trivalent Subunit Flu Vaccine in China
Ab&B Bio-Tech CO., LTD. JS, a Chinese vaccine developer specializing in premium and innovative vaccines aimed at replacing traditional and imported products in China while expanding globally, is advancing a pipeline that includes a trivalent subu...
Ab&B Bio-Tech Announces Board and Company Secretary Resignations
Ab&B Bio-Tech CO., LTD. JS announced that non-executive director and Audit Committee member Cheng Qianwen has tendered his resignation to focus on personal pursuits, but will remain in his roles until shareholders elect a new non-executive direct...
Ab&B Bio-Tech Shareholders Unanimously Back New INED and Auditor Reappointment
Ab&B Bio-Tech CO., LTD. JS reported that shareholders at its second extraordinary general meeting of 2025, held both onsite in Taizhou and online, approved all resolutions by poll with full support from the votes cast. Investors endorsed the appo...
Ab&B Bio-Tech Outlines Board Composition and Committee Roles
Ab&B Bio-Tech CO., LTD. JS has announced the current composition of its board of directors, which includes three executive directors, three non-executive directors and three independent non-executive directors, with chairman An Youcai serving as...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 17, 2026